CBD FOR AUTISM
A study from 2017 showed CBD increased the mice’s preference for spending time interacting with other mice and reduced the number of social anxiety-like behaviors. It demonstrated that CBD is beneficial for seizure frequency, duration, and severity and for autistic-like social deficits. This study provided critical support for CBD as a treatment of seizures in Dravet syndrome and autistic-like behaviors. (SOURCE)
A separate review summarizes the available pre-clinical and clinical data regarding the safety and effectiveness of CBD. This review suggests CBD seems to be a candidate for treatment of Autism Spectrum Disorder (ASD). (SOURCE).
Current arthritis treatments often have side-effects attributable to active compounds as well as route of administration. CBD attenuates inflammation and pain without side effects. A study published in 2015 looked at the topical CBD because it avoids gastrointestinal administration and first pass metabolism, which provides more constant plasma levels. The data from this study indicated that topical CBD application has therapeutic potential for relief of arthritis-pain related behaviours and inflammation without evident side-effects. x
CBD FOR ALZHEIMER’S DISEASE
A 2014 study was the first to demonstrate CBD’s ability to prevent the development of social recognition deficit in AD transgenic mice. The findins provide the first evidence that CBD may have potential as a preventative treatment for AD with a particular relevance for symptoms of social withdrawal and facial recognition. (SOURCE).
CBD FOR BRAIN DAMAGE
A fascinating study from 2017 shows that CBD reduces brain damage and improves functional recovery in animal models. Mice showed long-term functional recovery, reducing neuronal loss and astrogliosis, and modulating apoptosis, metabolic derangement, excitotoxicity and neuro-inflammation. (SOURCE).
Fragile X syndrome (FXS) is an X-linked dominant disorder caused by a mutation in the fragile X mental retardation 1 gene. CBD has shown therapeutic potential for individual with anxiety, poor sleep, and cognitive deficits, as well as populations with endocannabinoid deficiencies, such as those who suffer from FXS. A 2019 study reviewed recent animal and human studies of endocannabinoids in FXS and presented a case series describing three FXS patients who were treated with oral CBD. Findings hlight the importance of exploring the therapeutic potential of CBD. (SOURCE).
Neurological dysfuncations are the most impactful and persistent consequences of traumatic brain injury (TBI). A 2019 study showed that CBD administered orally restored the behavioral alterations and partially normalized the cortical biochemical changes. The data suggested that CBD could be a beneficial tool to improve neurological dysfunctions caused by the trauma. (SOURCE).
CBD FOR EPILEPSY
Over 50 million people worldwide suffer from epilepsy (more than Parkinson’s disease and cerebral palsy combined). It’s the fourth most common neurological disorder in the United States. Approximately a third of suffers (over 16 million) are unresponsive to antiepileptic medication and other medical treatments.
One of the most exciting developments in CBD research was the FDA approval of pure CBD isolate in a drug called Epidiolex. A study for drug-resistant seizures in the Dravet syndrome showed that CBD reduced the median number of seizures each month by 39% compared to 15% for placebo-treated patients. The study among patients with the Dravet syndrome concluded CBD resulted a greater reduction in convulsive-seizure frequency compared to a placebo. (SOURCE).
Another 2017 study focused on the use of CBD as a treatment for patients whose seizures had been non-responsive to prior treatments. The evaluation examined 15 patients and found that the frequency of seizures decreased by 40% between them. 60% of the patients were able to control half of their seizures, and in 27% of the patients, seizures completely disappeared. 100% of patients reported that their mood improved after the use of CBD, and the most common side-effects were drowsiness and fatigue. This study concluded that there is a possible beneficial effect of cannabidiol on the control of seizures and on the improvement of certain neurocognitive aspects in patients with refractory epilepsies (SOURCE).
A similar study explored the effects of CBD treatment in relation to seizures related to children with Dravet syndrome (DS). Dravet syndrome is a rare genetic epileptic neurological disorder that develops in the first year of a child’s life. It can cause developmental disabilities and is currently treated by a mix of medications that is unique to each child. The study showed that CBD-treated convulsive seizures were almost cut in half from 12.4% to 5.9%. The placebo group only decreased by 0.8%. Also, 5% of patients who were treated with a daily dose of CBD became seizure free. (SOURCE).
A 2015 review found research to suggest that CBD avoids the psychoactive effects of the endocannabinoid system to provide a well-tolerated therapy for the treatment of seizures. The review concluded that CBD can be sued to reduce seizures effectively in patients with treatment-resistant epilepsy. (SOURCE).
A 2014 study presented a summary of current scientific evidence about CBD with regards to their relevance to epilepsy and other neuropsychiatric disorders. It found that CBD has neuroprotectice and anti-inflammatory effects and is well tolerated in humans. The review concluded that CBD has a wide range of biologic effects with multiple potential sites of action in the nervous system. Preclinical evidence for anti-seizure properties and limited side effects support further development of CBD-based epilepsy treatments. (SOURCE).
CBD FOR GRAFT-VERSUS-HOST-DISEASE
Acute Graft-versus-host-disease (GVHD) is a major life-threaening complication following allogenic stem cell transplantation (alloSCT), affecting 35-70% of recipients despite standard prophylaxis regimens. CBD has shown beneficial ant-inflammatory and immunosuppressive properties so researched hypothesized CBD administration during alloSCT may significantly reduce GVHD incidence. A 2013 study complied data to conclude that the combination of CBD with standard GVHD prophylaxis is a safe and promising strategy to reduce the incidence of GVHD. (SOURCE).
CBD FOR PARKINSON’S DISEASE
Parkinson’s disease (PD) is a chronic neurodegenerative disorder characterized by motor symptoms such as bradykinesia, rest tremor, postural disturbances, and rigidity. PD is also characterized by non-motor symptoms such as sleep disturbances, cognitive deficits, and psychiatric disorders such as psychosis, depression and anxiety.
A 2019 review found seven preclinical models of PD using CBD, with six studies showing a neuroprotective effect of CBD. It also found three trials involving CBD and PD, and all three showed CBD to be well tolerated and demonstrated significant therapeutic effects in non-motor symptoms (psychosis, rapid eye movement sleep behavior disorder, daily activities and stigma). (SOURCE).
A 2014 study explored the effect of CBD in Parkinson’s disease globally with the UPDRS and the Parkinson’s Disease Questionnaire-39 (PDQ-39) used to asses overall functioning and well-being. The study found statistically significant differences in the variation between baseline and final assessment in the overall PDQ-39 score between the placebo and CBD, which suggests that there might be a possible effect of CBD on improving quality of life. (SOURCE).
CBD FOR MULTIPLE SCLEROSES
In adults with MS related spasticity, short term use of oral cannabinoids improve patient-reported spasticity symptoms (SOURCE).